Search Results
Nov 13, 2025, 08:00 ET Jobs to Move America Files Lawsuit Against Hyundai and Kia for Using Prison and Child Labor in U.S. Supply Chain
and federal law. The lawsuit alleges violations of California's Unfair Competition Law and is filed against Hyundai Motor America, Inc. ("HMA"), Hyundai Motor Company ("HMC"), Kia America, Inc. ("Kia"), Kia Corporation ("KC"), Hyundai Mobis Co. Ltd. ("Hyundai Mobis"), and Glovis America, LLC
More news about: Jobs to Move America
Nov 04, 2025, 07:30 ET Actinium Pharmaceuticals, Inc. to Highlight ATNM-400 Data in Hormone-Resistant and HER2-Resistant Breast Cancer at the 2025 San Antonio Breast Cancer Symposium, Expanding Pan-Tumor Profile Across Three Solid Tumor Indications
Actimab-A, Venetoclax (Abbvie/Roche) an oral Bcl-2 inhibitor and ASTX-727 (Taiho Oncology, an Otsuka holdings company) a novel oral hypomethylating agent (HMA) in frontline acute myeloid leukemia (AML) patients. Additionally, Actinium is developing Actimab-A as a potential pan tumor therapy in combination with
More news about: Actinium Pharmaceuticals, Inc.
Nov 03, 2025, 08:30 ET Actinium Pharmaceuticals, Inc. to Participate in the Stephens Biotechnology Virtual Fireside Chat Conference
Actimab-A, Venetoclax (Abbvie/Roche) an oral Bcl-2 inhibitor and ASTX-727 (Taiho Oncology, an Otsuka holdings company) a novel oral hypomethylating agent (HMA) in frontline acute myeloid leukemia (AML) patients. Additionally, Actinium is developing Actimab-A as a potential pan tumor therapy in combination with
More news about: Actinium Pharmaceuticals, Inc.
Oct 27, 2025, 07:00 ET Actinium Announces Superior Anti-Tumor Activity of ATNM-400 in Lung Cancer Compared to the Leading First, Second and Third-Line Approved EGFR Mutant Therapies and Mechanistic Synergy with Osimertinib at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
Actimab-A, Venetoclax (Abbvie/Roche) an oral Bcl-2 inhibitor and ASTX-727 (Taiho Oncology, an Otsuka holdings company) a novel oral hypomethylating agent (HMA) in frontline acute myeloid leukemia (AML) patients. Additionally, Actinium is developing Actimab-A as a potential pan tumor therapy in combination with
More news about: Actinium Pharmaceuticals, Inc.
Oct 24, 2025, 08:30 ET Actinium Pharmaceuticals Presents New Data Demonstrating Potent and Durable Efficacy of ATNM-400, a First-in-Class Multi-Tumor Actinium-225 Radiotherapy, at the 32nd Annual Prostate Cancer Foundation Scientific Retreat
Actimab-A, Venetoclax (Abbvie/Roche) an oral Bcl-2 inhibitor and ASTX-727 (Taiho Oncology, an Otsuka holdings company) a novel oral hypomethylating agent (HMA) in frontline acute myeloid leukemia (AML) patients. Additionally, Actinium is developing Actimab-A as a potential pan tumor therapy in combination with
More news about: Actinium Pharmaceuticals, Inc.
Oct 13, 2025, 12:10 ET Actinium Pharmaceuticals to Unveil the Multi-Tumor Potential of ATNM-400, a First-in-Class Actinium-225 Radiotherapy, with Data in Non-Small Cell Lung Cancer at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
Actimab-A, Venetoclax (Abbvie/Roche) an oral Bcl-2 inhibitor and ASTX-727 (Taiho Oncology, an Otsuka holdings company) a novel oral hypomethylating agent (HMA) in frontline acute myeloid leukemia (AML) patients. Additionally, Actinium is developing Actimab-A as a potential pan tumor therapy in combination with
More news about: Actinium Pharmaceuticals, Inc.
Oct 13, 2025, 08:30 ET Actinium to Present ATNM-400 Preclinical Data Highlighting Durable Tumor Control and Ability to Overcome Resistance to Standard-of-Care Prostate Cancer Therapies at the 32nd Annual Prostate Cancer Foundation Scientific Retreat
Actimab-A, Venetoclax (Abbvie/Roche) an oral Bcl-2 inhibitor and ASTX-727 (Taiho Oncology, an Otsuka holdings company) a novel oral hypomethylating agent (HMA) in frontline acute myeloid leukemia (AML) patients. Additionally, Actinium is developing Actimab-A as a potential pan tumor therapy in combination with
More news about: Actinium Pharmaceuticals, Inc.
Sep 30, 2025, 15:22 ET Healthcare Management Administrators Names Libby Moore as Chief People Officer
for enhancing high-performing workplace cultures and guiding key human resources initiatives at HMA. About Healthcare Management AdministratorsAt HMA, we are pioneering possibilities in healthcare®. Our team of dedicated professionals
More news about: Healthcare Management Administrators, Inc.
Sep 09, 2025, 08:17 ET HMA Expands Sales Team to Invest in Brokers and Local Markets Throughout Washington, Oregon, Utah, and Idaho
people and supporting them in their local communities," said Heather Hill, Vice President of Business Development at HMA. HMA specializes in self-funded employer benefits and offers tailored healthcare solutions such as competitive network discounts, advanced Payment Integrity
More news about: Healthcare Management Administrators, Inc.